Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Korea.
Department of Biomedical Informatics, Arizona State University, Scottsdale, AZ 85259, USA.
BMB Rep. 2018 Aug;51(8):373-377. doi: 10.5483/bmbrep.2018.51.8.127.
Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB4 receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC. [BMB Reports 2018; 51(8): 373-377].
三阴性乳腺癌（TNBC）因其侵袭性转移潜能和不良预后而被认为是一种恶性肿瘤。最近的证据表明，BLT2 是一种低亲和力的 LTB4 受体，与 TNBC 细胞的表型密切相关，包括侵袭、转移和存活。此外，在 545 例转移性乳腺癌患者中，我们观察到高 BLT2 亚组的无病生存率低于低 BLT2 亚组。因此，我们推测抗 BLT2 策略可以促进新的 TNBC 治疗方法的发展。本综述重点介绍了 BLT2 的最新发现及其作为 TNBC 新型预后生物标志物的作用。[BMB 报告 2018；51(8):373-377]。
